The February 2026 meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP) resulted in recommendations for twelve new medicines.¹ These outcomes, which included recommendations for ...
Continuing with the rare disease theme (Rare Disease Day is Feb 28), Elisabeth Gardiner of Tevard Biosciences explains in a video interview that research into ultra-rare conditions continues to yield ...
The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a ...
Asahi Kasei acquires Aicuris for €780M ($920M), adding anti-infective assets to its transplant and nephrology specialty pharmaceutical platform.
GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...
Univar Solutions LLC announced on February 24, 2026 that its Ingredients + Specialties from Univar Solutions division has been appointed as the distributor for Ingredion Pharma Solutions, creating an ...
One of the reasons why rare disease, medications take so long to get to the clinic is because we have very specific ...
Elisabeth Gardiner, PhD, is chief scientific officer at Tevard Biosciences, joining the leadership team in 2025 to spearhead the company’s pioneering tRNA-based gene therapies for rare diseases with ...
Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before ...
In response to Marty Makary warning the US may lose the early‑stage drug development lead to China, Brian Scanlan says speed, ...
In response to Marty Makary warning the US may lose the early‑stage drug development lead to China, Brian Scanlan says speed, ...
As sponsors advanced more niche and personalized modalities, manufacturers were pushed to adopt holistic approaches to safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results